SEAL Therapeutics
SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.
Date, time and room information
May 6, 15:30 - 15:45, room Singapore
Category
Emerging biotech company
Title of the presentation
SEAL Technology: AAV-mediated delivery of linker proteins to overcome severe muscular pathology
Speaker information
| Name | Position | Institution |
|---|---|---|
| Judith Reinhard, PhD | CSO | SEAL Therapeutics |
Host and event manager:
Logistics and marketing partner:
